ArticleFrontiers in oncology2020
Role of Heterotypic Neutrophil-in-Tumor Structure in the Prognosis of Patients With Buccal Mucosa Squamous Cell Carcinoma.
Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Correlation of Cell-in-Cell Structure With Prognosis in Solid Tumors-A Meta-Analysis.BioMed research international · 2025Pooled it
- Neutrophil Engulfment in Cancer: Friend or Foe?Cancers · 2025Review
- Colorectal cancer stem cells develop NK cell resistance via homotypic cell-in-cell structures suppressed by Stathmin1.Theranostics · 2025Article
- LncRNA MIR31HG facilitates immune escape in head and neck squamous cell carcinoma by promoting heterotypic cell-in-cell formation.American journal of cancer research · 2025Article
- Homotypic cell-in-cell structure as a novel prognostic predictor in non-small cell lung cancer and frequently localized at the invasive front.Scientific reports · 2024Article
- Loss of RND3/RHOE controls entosis through LAMP1 expression in hepatocellular carcinoma.Cell death & disease · 2024Article
- Article
- Tumor malignancy by genetic transfer between cells forming cell-in-cell structures.Cell death & disease · 2023Article
- Cell-in-cell: a potential biomarker of prognosis and a novel mechanism of drug resistance in cancer.Frontiers in oncology · 2023Review
- Subtype-based analysis of cell-in-cell structures in non-small cell lung cancer.American journal of cancer research · 2023Article
- AIM-CICs: an automatic identification method for cell-in-cell structures based on convolutional neural network.Journal of molecular cell biology · 2022Article
- Article
- Cell-in-cell structure mediates in-cell killing suppressed by CD44.Cell discovery · 2022Article
- Homotypic cell-in-cell structures as an adverse prognostic predictor of hepatocellular carcinoma.Frontiers in oncology · 2022Article
- Cell-in-Cell Events in Oral Squamous Cell Carcinoma.Frontiers in oncology · 2022Review
- Heterotypic neutrophil-in-tumor structure: A novel pathological feature first discovered in the tissues of OPSCC.Frontiers in oncology · 2022Article
- Cell-in-Cell: From Cell Biology to Translational Medicine.BioMed research international · 2022Review
- Molecular mechanisms underlying cell-in-cell formation: core machineries and beyond.Journal of molecular cell biology · 2021Article
- Cell-in-cell phenomenon: leukocyte engulfment by non-tumorigenic cells and cancer cell lines.BMC molecular and cell biology · 2021Article
- Role and dynamics of vacuolar pH during cell-in-cell mediated death.Cell death & disease · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo analyze the role of frequency of heterotypic neutrophil-in-tumor structure (FNiT) in the prognosis of patients with buccal mucosa squamous cell carcinoma (BMSCC).
methods
resultsFluorescent staining results of typical heterotypic neutrophil-in-tumor structure showed that well-differentiated H157 cells had a stronger ability to internalize more neutrophils than poorly-differentiated H157 cells, with the latter often internalizing only one neutrophil or nothing. The mean FNiT was 4.2‰, with a range from 2.3‰ to 7.8‰. A total of 80 patients relapsed and 84 patients died of the disease. The 5-year RFS and DSS rate was 42% and 42%, respectively. Patients with an FNiT≥4.2‰ had a significantly higher risk for locoregional recurrence and cancer-caused death than those with an FNiT<4.2‰ (p=0.001 and p<0.001, respectively). The FNiT alone was independently significant in predicting poor RFS, and the FNiT along with tumor grade was an independent predictor for DSS.
conclusionThe FNiT as a novel predictor is significantly negatively associated with both the RFS and DSS of patients with BMSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.